Member Info for chester18

As Cleanerworld has pointed our CEO Phil L’Huillier is listed as a Keynote Speaker at UK Biotech Day on 27–28 May.

ASCO 2026 conference starts this Friday 29th May until Tuesday 2nd June.

*A Keynote Speech followed by a conference that Scancell would normally make every effort to attend and have submitted Posters in the recent past*.

With my amazing ability to join any two dots no matter how convoluted, I have put the above two factors together and concluded ‘There Could be News’ this week.

Possibly - Maybe 🤔

EE

There is no argument from me about the points you raise. The approval of a Phase 3 has to be more rigorous than in phase 1 or 2 purely to do with the numbers involved. Then each trial has to be evaluated by people who understand that particular part of the medical science.

Are the MHRA under staffed or not fully equipped with all of the modern tools available to the FDA ? I don’t know but those could be reasons for causing such long delays.

Hopefully we will hear news of approval in the next couple of weeks 🤞🤞

EE

I think you would need to fully understand the process and the way the MHRA are setup. I think I’m right in saying that the approval board only sit a few time per month. Our institutions do have their faults but their job is to act as gatekeepers in the light of past tragic events.

If big pharma were that criminally minded I think would have had a BBC Special Investigation by now.

GLA

A very important part of the ModiFy Trial is the 15 patients Adjuvant & 15 patients Neo-Adjuvant in Head and Neck cancer.

That part of the study will be of great interest to any interested parties as it confirms both in the lab and in the patients exactly how deep Modi1 is infiltrating those tumours.

GLA

Hi Lemmyy

Absolutely fine, no need to apologise.

Glad to have you onboard 👍

Lemmyy

I thought I had just changed town’s 😂

Well done for finding Scancell and using science and clinical validation for your investment.

I’m also waiting to see the Modi1 phase 1/2 trial update promise in H1/26.

There are many parts to that trial and the data has been building for some time so it could be very interesting when it arrives.

Thank you Lemmyy

It is good to have a point of view from outside of the UK voices.

We still await news about approval from the EMA but it may follow on from MHRA.

Scancell is very close to creating a big news event especially in the face of Melanoma cases increasing rapidly worldwide.

Maybe some news on Tuesday about any involvement at ASCO.

GLA

Excellent JB1

I’ve taken a screenshot of that graph for future reference. Good info thanks.

C18 👊

Thank you Berm

I hope this board doesn’t lose its identity when Scancell starts to rise in popularity.

The clinical details of past trials are a complex trail and for many like myself who come from different working backgrounds it is fantastic to ask for help and receive it in abundance.

The sooner Scancell have the Ph3 under way the better for the sake of all melanoma sufferers as can see a successful trial leading to iScib1+ and possibly SCIB1 Mono being trickledown down through many other areas of the disease.

Once again thank you for sharing your knowledge and helping all of us to keep to the correct facts.

👊

Thank you Vascular,

Selected from that news article that is dated 4 years ago - 13/04/2022.

“The six-month PFS was 34% for patients who received the combination compared with 13% for those who received ipilimumab alone. At a median follow-up of 24.4 months, 39 patients who were given ipilimumab plus nivolumab had died, compared with 12 who had received ipilimumab. Mario Sznol, MD, a professor of medicine (medical oncology) with Smilow Cancer Hospital at Yale New Haven in Conn., served as a discussant for the AACR session and noted that the difference in PFS between the two arms closed after six months.

“Although that six-month PFS looks very nice, 34% versus 13% with a single agent, the durable PFS difference declines to less than 10% by 18-24 months. [It’s] an impressive result, but not as impressive as we would have liked,” he said.

I think the subsequent phase 3 trial produced the PFS figures used by Scancell.

Not a definitive 24 month report but it clearly shows that our current 77% is a massive improvement from those earlier studies.

Scancell’s immunotherapy is a real game changer in the fight against Melanoma cancer.

👊👊

Thanks Ray

Having the information of what that 24 month PFS percentage was will allow us to see if there is a continued drop off and roughly at what rate per month or quarter.

For instance, if the SOC at 24 months dropped to 38% and our figure was static we’ll hold a 39% advantage. In other words the chance of the treatment keeping you safe will be doubled on iScib1+.

That would make for some serious headlines across all news media.

We have seen from Scancell’s iScib1+, Data updates, that the SOC at 11.5 months was 50% and at 20 months it was 43%.

Where can I find the publish percentage figure for SOC PFS at 24 months ?

I’m interested in seeing if there was a further decline. Our 24 months PFS will not be known until August but we do know ours was 74% in December 2025 ( 16 months ) and improved to 77% in April 2026 ( 20 months ).

If anyone can either recommend where I can find that figure or if it’s known to anyone I would appreciate the help.

GLA …..

I must add to my last post.

The ModiTope Modi1 trial is conducted in late stage cancer patients so any success with those cancers is massively life changing for the patients on the trial. The current prognosis in those late cancers is not good and even a 10% or 20% improvement is so badly needed.

GLA.

The ModiTope trial phase 1/2 was described by Lindy as a ‘basket trial’. The number of patients was restricted and various arms of the trial were designed to better understand where Modi1 gained the best clinical results.

I think because iSCIB1+ added to Double Checkpoints has shown very positive results there is an anticipation that Modi1 will also succeed with the Double Checkpoints.

Modi1 used as a Mono-therapy in Ovarian Cancer and Breast Cancer did show clinical positive results but probably needs either a single or double checkpoint to excel. We’ll find out in the next 5 weeks 👊👊

ModiTope is why I’m a shareholder iScib1+ is a fantastic bonus.

After Phil’s show of frustration at the hands of MHRA I’m hoping there have been a few irate phone calls made by the attendees at the Lords.

The way he described the outstanding issues revealed his personal view of their attitude towards speed. There is none !

So the next two or three weeks should see that approval over the line.

I would hope that we are represented at ASCO as it would defy all logic if we’re not.

GLA…… 👊

The sell off had a lot of panic written in and I would expect that anyone who has seriously researched Scancell would realise what the potential value really is.

One piece of positive news and we will see the return of all those who left too quickly.

GLA

In light of the last days trading I think it’s correct to point out what the reality is of actually holding Scancell shares.

( first posted 13/05/26 )

FDA Approval to run a Phase 3 medical trial in the USA and FDA Fast Track Designation.

34% Improvement in ‘Progression Free Survival’ over current Standard of Care.

You cannot Chart that kind of potential because the ensuing partnership deal or outright sale are extremely possible and very difficult to value correctly.

Profits will be taken but when that news lands the SP could ( I’m not saying ‘will’ ) double in the first 5 mins of trading.

That is now the reality of owning Scancell shares.

I wish everyone holding stock or watching and waiting to jump in the very best of luck with your own personal decisions.

EE

Read what I wrote properly.

“Looks like we are watching a domino effect from yesterday’s comments about MHRA approval not quite there and the fact that Scancell may be forced to seek finance from a NasDaq listing to push on with the Phase 3 trial”.

“Scancell may be forced” which is what Phil was saying so it is a fact.

I appreciate there are many other routes to finance.

Looks like we are watching a domino effect from yesterday’s comments about MHRA approval not quite there and the fact that Scancell may be forced to seek finance from a NasDaq listing to push on with the Phase 3 trial.

This is a literal response to a partial disclosure of sorts. We still await MHRA approval but it would seem to be small factors and probably mainly concerned with the trial set up, execution and administration.

The data from SCOPE is still growing daily and we’re only a few weeks from the ModiTope data update.

AIM is market full of short term thinking but I for one still believe that BMS will not allow either an independent Scancell or a Rival to land ‘Standard of Care’ and remove a potential £3billion a year revenue. Especially because iSCIB1+ then will move into earlier settings and remove even more long term revenue. Also importantly, BMS will lose any chance of registering a new patent and secure the next 15 years growth.

So it’s a shame everyone with a short term blinkers is running to the door because it can turnaround very quickly.

Interesting comments from our CEO today.

The comments about raising capital and the restrictions in the UK pushing Scancell to view a NasDaq listing were in context to the Parliamentary Sub Committee questions and agenda.

This was not the platform to disclose any information about potential partners or Big Pharma interest. Those details were not in any way part of today’s discussions but funding British enterprises was.

The MHRA seems to be either massively under staffed / funded or operating like a 1950’s bureaucratic ‘advancement prevention committee’.

Phil was frustrated by the fact that the MHRA were being so pedantic when they had all the facts and data from the phase 1 and 2 trials.

Let’s hope someone at today’s committee has the authority to give the MHRA prevention officers a bit of a kick up the pants.